Personalized Medicine and Anti-EGFR Antibody Therapy in the Treatment of Metastatic Colorectal Cancer: KRAS and Beyond

被引：0
|
作者：
Chu, Edward [1 ]
机构：
[1] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15260 USA
来源：
ONCOLOGY-NEW YORK | 2014年 / 28卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：96 / 96
页数：1
相关论文
共 50 条
  • [21] Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
    Gattenloehner, S.
    Etschmann, B.
    Kunzmann, V.
    Thalheimer, A.
    Hack, M.
    Kleber, G.
    Einsele, H.
    Germer, C.
    Mueller-Hermelink, H. -K.
    JOURNAL OF ONCOLOGY, 2009, 2009
  • [22] Clinical translation of predictive markers for anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer
    Rowland, Andrew
    Karapetis, Christos S.
    Mangoni, Arduino A.
    Wiese, Michael D.
    Kichenadasse, Ganessan
    McKinnon, Ross A.
    Sorich, Michael J.
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S31 - S34
  • [23] EGFR protein expression of the metastatic colorectal cancer as a prognostic/predictive factor for anti-EGFR antibody therapy.
    Timar, Jozsef
    Piurko, Violetta
    Kenessey, Istvan
    Raso, Erzsebet
    Lahm, Erika
    Kiss, Edina
    Sikter, MArta
    Vachaja, Jozsef
    Papai, Zsuzsa
    Uhlyarik, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer
    Jose A. García-Sáenz
    Javier Sastre
    Eduardo Díaz-Rubio García
    Clinical and Translational Oncology, 2009, 11 : 737 - 747
  • [25] Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
    Sandra Misale
    Rona Yaeger
    Sebastijan Hobor
    Elisa Scala
    Manickam Janakiraman
    David Liska
    Emanuele Valtorta
    Roberta Schiavo
    Michela Buscarino
    Giulia Siravegna
    Katia Bencardino
    Andrea Cercek
    Chin-Tung Chen
    Silvio Veronese
    Carlo Zanon
    Andrea Sartore-Bianchi
    Marcello Gambacorta
    Margherita Gallicchio
    Efsevia Vakiani
    Valentina Boscaro
    Enzo Medico
    Martin Weiser
    Salvatore Siena
    Federica Di Nicolantonio
    David Solit
    Alberto Bardelli
    Nature, 2012, 486 : 532 - 536
  • [26] Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
    Misale, Sandra
    Yaeger, Rona
    Hobor, Sebastijan
    Scala, Elisa
    Janakiraman, Manickam
    Liska, David
    Valtorta, Emanuele
    Schiavo, Roberta
    Buscarino, Michela
    Siravegna, Giulia
    Bencardino, Katia
    Cercek, Andrea
    Chen, Chin-Tung
    Veronese, Silvio
    Zanon, Carlo
    Sartore-Bianchi, Andrea
    Gambacorta, Marcello
    Gallicchio, Margherita
    Vakiani, Efsevia
    Boscaro, Valentina
    Medico, Enzo
    Weiser, Martin
    Siena, Salvatore
    Di Nicolantonio, Federica
    Solit, David
    Bardelli, Alberto
    NATURE, 2012, 486 (7404) : 532 - U131
  • [27] Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer
    Garcia-Saenz, Jose A.
    Sastre, Javier
    Diaz-Rubio Garcia, Eduardo
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2009, 11 (11): : 737 - 747
  • [28] KRAS/BRAF Mutation status as a predictive Biomarker for Anti-EGFR Antibody therapy in primary and metastatic colorectal carcinoma.
    Mayer, B.
    Bogner, A.
    Jauch, K. -W
    Singer, T.
    ONKOLOGIE, 2010, 33 : 151 - 151
  • [29] Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy
    Cristiana Lo Nigro
    Vincenzo Ricci
    Daniela Vivenza
    Cristina Granetto
    Teresa Fabozzi
    Emanuela Miraglio
    Marco C Merlano
    World Journal of Gastroenterology, 2016, (30) : 6944 - 6954
  • [30] KRAS mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine
    Coupez, Dahna
    Hulo, Pauline
    Touchefeu, Yann
    Denis, Marc G.
    Bennouna, Jaafar
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (10) : 1325 - 1334
12345